- Details
- Description
-
Packaging Size120t/Bollte
-
Strength20mg
-
CompositonLinperlisib
-
TreatmentRelapsed or refractory (r/r) Follicular lymphoma (FL)
-
FormTablet
-
Brand因他瑞
-
Quantity Unit20mg*120t/Box
-
ManufacturerYingli Pharmaceutical Co., Ltd.,China
Linperlisib, a next-generation PI3Kδ-selective oral inhibitor, received marketing approval in China in 2022 for treatment of patients with relapsed and/or refractory follicular lymphoma after two or more systemic therapies. Linperlisib also received U.S. FDA Orphan Drug Designations for follicular lymphoma, chronic lymphocytic leukemia, and T cell lymphomas.
- Linperlisib sold under the brand name 因他瑞® in china.
[Dosage and Administration]
The recommended dosage is 80 mg/time (4 tablets, each containing 20 mg of Linperlisib), taken once a day, before or after meals, until disease progression or intolerable toxicity occurs.
Precautions During and after treatment with limplicel tablets, Pneumocystis jiroveci pneumonia (PJP) should be prevented until the absolute CD4+ T lymphocyte count is greater than 200 cells/µL.
For any patient suspected of PJP, limplicel tablets should be suspended; patients diagnosed with PJP should stop taking limplicel tablets.
During treatment with Linperlisib tablets, prophylactic use of antiviral drugs may be considered to prevent cytomegalovirus (CMV) infection and reactivation.
Dose adjustment Depending on the safety and tolerability of individual patients, it may be necessary to suspend the drug, reduce the dose, or permanently stop the drug.
